Aquestive Therapeutics (NASDAQ:AQST) posted its quarterly earnings data on Tuesday. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.49) by ($0.15), Fidelity Earnings reports. The firm had revenue of $13.27 million for the quarter, compared to the consensus estimate of $14.75 million.
AQST traded up $0.36 during trading on Wednesday, reaching $17.91. 78,712 shares of the stock were exchanged, compared to its average volume of 130,135. Aquestive Therapeutics has a twelve month low of $13.61 and a twelve month high of $20.70.
A number of research firms have recently issued reports on AQST. Royal Bank of Canada set a $24.00 price objective on shares of Aquestive Therapeutics and gave the company a “buy” rating in a report on Wednesday. Wedbush set a $34.00 price objective on shares of Aquestive Therapeutics and gave the company a “buy” rating in a report on Thursday, October 25th. JMP Securities began coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They issued an “outperform” rating and a $29.00 price objective on the stock. Finally, BMO Capital Markets began coverage on shares of Aquestive Therapeutics in a report on Monday, August 20th. They issued an “outperform” rating on the stock.
An institutional investor recently bought a new position in Aquestive Therapeutics stock. Engineers Gate Manager LP bought a new position in shares of Aquestive Therapeutics Inc (NASDAQ:AQST) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 26,511 shares of the company’s stock, valued at approximately $464,000. Engineers Gate Manager LP owned about 0.11% of Aquestive Therapeutics at the end of the most recent quarter. 1.22% of the stock is currently owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of US & international copyright laws. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/aquestive-therapeutics-aqst-posts-earnings-results-misses-expectations-by-0-15-eps.html.
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. Its products are developed using its PharmFilm technology. The company's marketed products include Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron antagonist for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.